No Data
What kind of company is Natera, the largest hold positions of Drew Miller?
Currently, there is a lack of precision in adjuvant therapy plans after tumor (MRD) surgery, while MRD testing can detect molecular abnormalities originating from the tumor, enabling early detection of cancer recurrence and guiding precise postoperative treatment. Huayuan Securities believes that natera's MRD testing business has significant competitive advantages, and its launched Signatera product is expected to become the core driving force behind the company's rapid performance improvement.
Weekly Buzz: Not All Parties Last Forever
Market Falls to End All-Time High Week | Wall Street Today
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Large Pharmas, Biotechs Down as Industries Grapple With RFK Jr. at HHS
U.S. Pharma Is Largely Immune From 'MAHA' Impact: Wolfe